Delivery Order SPE2DB20D2104-SPE2DB25FMZZT
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $4,097.65 to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Eliquis 2.5 mg tablets in quantities of 60 units. The contract is a firm fixed price delivery order with an ultimate completion date of September 2, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This award carries no set-aside designation and was competitively awarded, reflecting AmerisourceBergen's capability...
- The Defense Logistics Agency awarded a delivery order valued at $1,591.08 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count packaging) on August 13, 2025, with an ultimate completion date of August 14, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a single transaction under AmerisourceBergen's existing contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Eliquis 5 mg tablets (60-count units) with a ceiling value of $14,787.00. This firm fixed-price delivery order, which is set to be completed by August 12, 2025, will be fulfilled from the vendor's Conshohocken, Pennsylvania location. The award represents a competitive procurement with no set-aside designation, reflecting AmerisourceBergen's demonstrated capability to meet...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Eliquis 5 mg tablets (60-count packages) valued at $13,452.67. This firm fixed-price delivery order is scheduled for completion by July 21, 2025, and will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a non-competitive delivery order issued without set-aside restrictions, drawing from AmerisourceBergen's existing...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $14,259.49 to AmerisourceBergen Drug Corp for the supply of Eliquis 2.5 mg tablets (60-count units) on August 22, 2025, with an ultimate completion date of August 25, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in...
- The Defense Logistics Agency awarded a delivery order valued at $1,965.60 to AmerisourceBergen Drug Corp for the supply of Eliquis 2.5 mg tablets (60-count packages) on July 29, 2025, with completion targeted for July 30, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The pharmaceutical will be delivered to the Conshohocken, Pennsylvania location, which serves as AmerisourceBergen's corporate headquarters and primary distribution...
- The Defense Logistics Agency awarded a delivery order valued at $39,626.90 to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Eliquis 5 mg tablets (60-count units). This firm fixed price contract, which is a child order under a larger indefinite delivery vehicle, requires completion by August 28, 2025, with performance taking place at the vendor's corporate office location in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside...
- The Defense Logistics Agency awarded a delivery order valued at $1,965.60 to AmerisourceBergen Drug Corp for the supply of Eliquis 2.5 mg tablets (60-count) on September 10, 2025, with an ultimate completion date of September 11, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a routine pharmaceutical procurement supporting federal...
- The Defense Logistics Agency awarded a delivery order valued at $5,514.22 to AmerisourceBergen Drug Corp for the supply of Eliquis 5 mg tablets (60-count) on August 5, 2025, with completion scheduled for August 6, 2025. This competitive award, issued on a firm fixed-price basis with no set-aside designation, represents a child delivery order executed under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The pharmaceutical product will be delivered to...
- The Defense Logistics Agency awarded a $2,214.72 delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Eliquis 5 mg tablets (60-count packages). This is a firm fixed-price contract with a completion date of August 14, 2025, and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The contract was competitively awarded with no set-aside designation. Performance will occur at...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FMZZTDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,965.60 to AmerisourceBergen Drug Corp for the supply of Eliquis 2.5 mg tablets (60-count units) on September 10, 2025, with a completion date of September 11, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. This delivery order is issued under AmerisourceBergen Drug Corp's prime IDC (SPE2DX) with the Defense Logistics Agency, valued at $999,999,999.00 and extending through December 2026. The prime contract serves as a comprehensive global pharmaceutical support vehicle enabling the supply of medications, vaccines, and medical supplies to military healthcare systems worldwide, including support for the Defense Health Agency and U.S. Coast Guard. AmerisourceBergen, a major pharmaceutical distributor headquartered in Pennsylvania, has demonstrated consistent capability to fulfill federal medical procurement requirements across a broad spectrum of therapeutic domains through competitive federal contracting.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.0k | 9/10/25 |